Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
Sponsor: NewAmsterdam Pharma
Summary
The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab Patients will: Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16
Official title: A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT Study
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
69
Start Date
2024-12-02
Completion Date
2027-02
Last Updated
2026-04-09
Healthy Volunteers
No
Conditions
Interventions
obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
10 mg obicetrapib for 8 weeks followed by 10 mg obicetrapib/ 140 mg evolocumab (every 2 weeks) combination for 8 weeks
Locations (1)
UPenn
Philadelphia, Pennsylvania, United States